Your browser doesn't support javascript.
loading
Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing.
Evans, D Gareth; King, Andrew T; Bowers, Naomi L; Tobi, Simon; Wallace, Andrew J; Perry, Mary; Anup, Raji; Lloyd, Simon K L; Rutherford, Scott A; Hammerbeck-Ward, Charlotte; Pathmanaban, Omar N; Stapleton, Emma; Freeman, Simon R; Kellett, Mark; Halliday, Dorothy; Parry, Allyson; Gair, Juliette J; Axon, Patrick; Laitt, Roger; Thomas, Owen; Afridi, Shazia; Ferner, Rosalie E; Harkness, Elaine F; Smith, Miriam J.
Afiliação
  • Evans DG; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK. gareth.evans@mft.nhs.uk.
  • King AT; Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Bowers NL; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
  • Tobi S; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
  • Wallace AJ; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
  • Perry M; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
  • Anup R; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
  • Lloyd SKL; Department of Otolaryngology, Manchester Royal Infirmary, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Manchester, UK.
  • Rutherford SA; Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Hammerbeck-Ward C; Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Pathmanaban ON; Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Stapleton E; Department of Otolaryngology, Manchester Royal Infirmary, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Manchester, UK.
  • Freeman SR; Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Kellett M; Department of Otolaryngology, Manchester Royal Infirmary, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Manchester, UK.
  • Halliday D; Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Parry A; Department of Neurology, Manchester Centre for Clinical Neurosciences, Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Gair JJ; Oxford Centre for Genomic Medicine, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, UK.
  • Axon P; Oxford Centre for Genomic Medicine, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, UK.
  • Laitt R; Department of Otolaryngology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Thomas O; Department of Otolaryngology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Afridi S; Department of Neuroradiology, Manchester Centre for Clinical Neurosciences, Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Ferner RE; Department of Neuroradiology, Manchester Centre for Clinical Neurosciences, Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Harkness EF; Department of Neurology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Smith MJ; Department of Neurology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Genet Med ; 21(7): 1525-1533, 2019 07.
Article em En | MEDLINE | ID: mdl-30523344
ABSTRACT

PURPOSE:

We have evaluated deficiencies in existing diagnostic criteria for neurofibromatosis 2 (NF2).

METHODS:

Two large databases of individuals fulfilling NF2 criteria (n = 1361) and those tested for NF2 variants with criteria short of diagnosis (n = 1416) were interrogated. We assessed the proportions meeting each diagnostic criterion with constitutional or mosaic NF2 variants and the positive predictive value (PPV) with regard to definite diagnosis.

RESULTS:

There was no evidence for usefulness of old criteria "glioma" or "neurofibroma." "Ependymoma" had 100% PPV and high levels of confirmed NF2 diagnosis (67.7%). Those with bilateral vestibular schwannoma (VS) alone aged ≥60 years had the lowest confirmation rate (6.6%) and reduced PPV (80%). Siblings as a first-degree relative, without an affected parent, had 0% PPV. All three individuals with unilateral VS and an affected sibling were proven not to have NF2. The biggest overlap was with LZTR1-associated schwannomatosis. In this category, seven individuals with unilateral VS plus ≥2 nondermal schwannomas reduced PPV to 67%.

CONCLUSIONS:

The present study confirms important deficiencies in NF2 diagnostic criteria. The term "glioma" should be dropped and replaced by "ependymoma." Similarly "neurofibroma" should be removed. Dropping "sibling" from first-degree relatives should be considered and testing of LZTR1 should be recommended for unilateral VS.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bases de Dados Factuais / Neurofibromatose 2 Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bases de Dados Factuais / Neurofibromatose 2 Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article